H 89 2HCl: Selective Protein Kinase A Inhibitor for cAMP/PKA Pathway Dissection

Executive Summary: H 89 2HCl (SKU: B2190, APExBIO) is a potent and selective inhibitor of protein kinase A (PKA), exhibiting a Ki of 48 nM in cell-free assays and over 10-fold selectivity for PKA over PKG. It robustly blocks cAMP-dependent protein phosphorylation without altering intracellular cAMP levels, enabling precise dissection of PKA-specific signaling pathways in vitro and in vivo (Wang et al. 2021). The compound demonstrates well-characterized inhibition of forskolin-induced neurite outgrowth and histone IIb phosphorylation in PC12D cells. Its application spans bone remodeling, neurobiology, and cancer studies, where it provides actionable, reproducible kinase inhibition benchmarks. Researchers must heed its solubility limits and selectivity profile to avoid common pitfalls in experimental design (APExBIO product page).

Biological Rationale

Protein kinase A (PKA) is a serine/threonine kinase ubiquitously expressed in eukaryotic cells. It is a central mediator of cyclic AMP (cAMP) signaling, influencing gene expression, metabolism, neuronal differentiation, and cell proliferation (Wang et al. 2021). Aberrant PKA activity is implicated in neurodegenerative diseases, cancer, and metabolic bone disorders. Pharmacological inhibition of PKA is essential to dissect the role of cAMP/PKA signaling in these physiological and pathological contexts. H 89 2HCl, also known as (E)-N-(2-((3-(4-bromophenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide dihydrochloride or N-(2-(p-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide, is engineered to provide high specificity and potency for such studies (APExBIO).

Mechanism of Action of H 89 2HCl

H 89 2HCl competitively inhibits the ATP binding site of PKA catalytic subunits. Its Ki is 48 nM under cell-free conditions (pH 7.4, 25°C) (APExBIO). It exhibits approximately 10-fold selectivity for PKA over PKG and over 500-fold selectivity versus PKC, MLCK, calmodulin kinase II, and casein kinase I/II. H 89 2HCl also inhibits kinases such as S6K1 (IC50 ≈ 80 nM), MSK1, ROCKII, PKBα, and MAPKAP-K1b (IC50 80–2800 nM), but with reduced potency. Notably, H 89 2HCl does not affect intracellular cAMP levels. In PC12D cells, it dose-dependently blocks forskolin-induced neurite outgrowth and histone IIb phosphorylation, affirming its specificity for cAMP/PKA-dependent events (Wang et al. 2021).

Evidence & Benchmarks

• H 89 2HCl inhibits PKA catalytic activity with a Ki of 48 nM in cell-free assays (pH 7.4, 25°C) (APExBIO).
• It shows 10-fold selectivity over PKG and >500-fold selectivity over PKC, MLCK, calmodulin kinase II, and casein kinase I/II (APExBIO).
• In PC12D cells, H 89 2HCl blocks forskolin-induced neurite outgrowth and histone IIb phosphorylation in a dose-dependent manner (Wang et al. 2021).
• In RAW cells, H 89 2HCl abrogates cAMP/PKA/CREB pathway activation, confirming mechanistic specificity in osteoclast differentiation models (Wang et al. 2021).
• H 89 2HCl is soluble at ≥51.9 mg/mL in DMSO but insoluble in water and ethanol, requiring DMSO-based protocols for in vitro use (APExBIO).

This article extends previous guides (see here) by integrating new benchmarks from osteoclastogenesis and highlighting updated selectivity data for translational research.

Applications, Limits & Misconceptions

H 89 2HCl is validated for use in:

• Dissecting cAMP/PKA signaling in bone biology, especially for studying dopamine-mediated suppression of osteoclast differentiation (Wang et al. 2021).
• Neurobiology, such as inhibition of neurite outgrowth in PC12D cells via PKA-dependent pathways (internal guide).
• Cancer research, where precise modulation of protein phosphorylation is required (benchmark article).

However, H 89 2HCl has known off-targets at higher concentrations, including S6K1 (IC50 ≈ 80 nM) and other kinases up to 2.8 μM. Selectivity must be empirically verified for each model system.

Common Pitfalls or Misconceptions

• Assuming complete exclusivity for PKA: H 89 2HCl inhibits additional kinases at higher doses (APExBIO).
• Using aqueous or ethanol solutions: The compound is insoluble in water or ethanol; only DMSO ensures reliable stock preparation.
• Assuming cAMP levels are affected: H 89 2HCl does not reduce intracellular cAMP; it only inhibits downstream PKA activity (Wang et al. 2021).
• Misapplying storage guidelines: Degradation occurs if solutions are not used promptly; store solid at -20°C (APExBIO).
• Generalizing results across all cell types: Off-target effects may vary with cell context and expression of secondary kinases.

This article clarifies boundaries that were only briefly addressed in prior coverage (see here), providing explicit guidance for selectivity and solubility.

Workflow Integration & Parameters

For optimal use of H 89 2HCl:

• Prepare stocks at ≤51.9 mg/mL in DMSO; dilute immediately before use (APExBIO).
• Store solid at -20°C; avoid repeated freeze-thaw cycles of solutions.
• Use in cell-free or cell-based assays at concentrations empirically determined for specificity (commonly 0.1–10 μM).
• Include vehicle controls (DMSO) and kinase selectivity panels if possible.

For advanced troubleshooting and workflows, see the updated protocol guide, which this article expands upon with new application notes (internal guide).

Conclusion & Outlook

H 89 2HCl remains a gold-standard reagent for dissecting cAMP/PKA signaling in diverse biological models. Its selective inhibition of PKA, combined with well-characterized off-target profiles, empowers researchers to assign phenotypes to PKA-dependent pathways with confidence. Future research may refine its use in in vivo settings and complex disease models. For additional details or to order the compound, see the H 89 2HCl product page (APExBIO).